James C. Gale
Chairman of the Board
Mr. Gale is the founding partner of Signet Healthcare Partners. He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent Inc., and also serves on the board of directors of Spepharm AG, Bionpharma Inc., CoreRx, Inc., Leon Nanodrugs GmbH, Pharmaceuticals International Inc. and Chr. Olesen Synthesis A/S. Prior to Signet, Mr. Gale worked for Gruntal & Co., LLC as head of principal investment activities and investment banking. Prior to joining Gruntal, he worked in Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale holds an M.B.A. from the University of Chicago. Mr. Gale was on the Board of Paladin Labs from 2008 to 2014.
Jonathan Ross Goodman
Director, CEO and founder
Mr. Goodman founded Knight in February 2014. Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $151 nineteen years later. Prior to co-founding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University. In 2016, Mr. Goodman was the co-recipient of Ernst & Young’s Quebec Entrepreneur of the Year Award in Health Sciences.
Director, President and CFO
Ms. Sakhia joined Knight as President in August 2016 and assumed the additional responsibility of CFO in October 2017. Prior to Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the TSX and completed the sale of Paladin to Endo International for over $3 billion. Ms. Sakhia serves on the board of Profound Medical Corporation. In addition, Ms. Sakhia serves on the board of the Montreal Society for the Prevention of Cruelty to Animals, the International Advisory Board of McGill’s Desautels Faculty of Management, and is an independent Board member at the McGill University Health Center. Ms. Sakhia holds an MBA and a Bachelors of Commerce degree from McGill University and is also a Chartered Professional Accountant.
Mr. Lande is the Chief Financial Officer of FXCM, Inc. a foreign exchange brokerage firm. Formerly, he was managing partner and Chief Operating Officer of Riveredge Capital Partners LLC. Prior to Riveredge Capital, Mr. Lande worked for over 16 years within the BCE/Bell Canada group where his last position was Chief Financial Officer of Telecom Américas Ltd., a joint venture between Bell Canada International, AT&T (then SBC Communications) and America Movil. Mr. Lande is chartered financial analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University. Mr. Lande was on the Board of Paladin Labs from 1995 to 2014.
Ms. Tendler is a leading pharmaceutical market research specialist. In 2001, she founded The Tendler Group, a custom pharma marketing research consulting company which served 12 of the Top 20 global pharmaceutical companies. She led The Tendler Group until its sale to IntrinsiQ LLC in 2007 where she remained as President of IntrinsiQ Tendler until 2010. Ms. Tendler has hands-on experience conducting global primary research in the top 5 EU markets, as well as USA, Brazil and Mexico and has been involved in the development and launch of blockbuster prescription products across therapeutic categories. Ms. Tendler holds a Master’s degree in International Management from the University of Maryland.
Ms. Harrison is Co-founder and former President of MSI Methylation Sciences, a private venture backed development company with a novel treatment of depression in a Phase II clinical trial. Ms. Harrison is a former Partner and Senior Vice President of Ventures West Management Inc. and spent 13 years with Ventures West leading its life sciences practice in Canada and the U.S. Ms. Harrison is one of the most experienced life sciences investors in the Canadian venture capital industry and was instrumental in Ventures West’s involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Salmedix Inc. and Oncogenix Pharmaceuticals Inc., Celator Pharmaceuticals Inc., and Caprion BioSciences. During her time with Ventures West, the firm grew from approximately $80 million to over $750 million. Ms. Harrison has an undergraduate degree in Engineering from Queen’s University and an MBA from McGill University.
Michael J. Tremblay
Mr. Tremblay has over 40 years of experience in the pharmaceutical industry. In 2018, he retired from Astellas Pharma Canada, Inc. where he served as President of Canadian operations. He joined the company in June 2000 and held various positions within the organization’s commercial area before being appointed to the President’s position in 2010. Prior to joining Astellas, Mr. Tremblay held positions at Janssen Canada Inc., Searle Canada Inc., Baxter-Travenol Canada and Smith, Kline and French Canada. Mr. Tremblay has sat on a number of Boards including Community & Home Assistance to Seniors (“CHATS”) and Innovative Medicines Canada (“IMC”), the organization representing the leading research-based pharmaceutical companies in Canada. Mr. Tremblay began serving on the Board at IMC in 2011 and was elected Chair of the Board in 2015 and held that position until November 2017. Mr. Tremblay holds a B.Sc. in Biology and Chemistry from the University of Windsor.
Mr. Cameron is the Chief Executive Officer of Ionetix Corporation, a privately held biotechnology company focused on providing diagnostic imaging agents and radiotherapeutics. Before joining Ionetix, Mr. Cameron was the co-founder and President of Glass Lewis & Co., a leading provider of corporate governance services to institutional investors. Prior to that, Mr. Cameron was with Maxi Digital and NorthPoint Communications. Mr. Cameron started his career as an attorney with the law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C., and served as a law clerk for the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron currently serves as a board member of Xyphos Biosciences, a biotechnology company focused on next generation CAR-T therapy. Mr. Cameron also serves as a board member of ProCure Treatment Centers, a leading developer of proton therapy centers, and previously served as a director of Keryx Biopharmaceuticals, a biopharmaceutical company focused on therapies for renal patients, as well as on the Boards of AvidBiotics, Reddy Ice and Ecototality. Mr. Cameron holds a law degree from the University of Chicago and an undergraduate degree from McGill University.